Novartis AG ADR [NYSE: NVS] loss -0.43% on the last trading session, reaching $103.40 price per share at the time.
If compared to the average trading volume of 2.38M shares, NVS reached a trading volume of 4207292 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Novartis AG ADR [NVS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVS shares is $118.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVS stock is a recommendation set at 2.97. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Novartis AG ADR shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on February 13, 2025. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Underweight. The new note on the price target was released on February 12, 2025, representing the official price target for Novartis AG ADR stock.
The Average True Range (ATR) for Novartis AG ADR is set at 3.04, with the Price to Sales ratio for NVS stock in the period of the last 12 months amounting to 3.90. The Price to Book ratio for the last quarter was 4.64, with the Price to Cash per share for the same quarter was set at 7.09. Price to Free Cash Flow for NVS in the course of the last twelve months was 12.07 with Quick ratio for the last quarter at 0.84.
Trading performance analysis for NVS stock
Novartis AG ADR [NVS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.89. With this latest performance, NVS shares dropped by -4.82% in over the last four-week period, additionally sinking by -9.11% over the last 6 months – not to mention a rise of 7.92% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVS stock in for the last two-week period is set at 37.72, with the RSI for the last a single of trading hit 33.80, and the three-weeks RSI is set at 41.18 for Novartis AG ADR [NVS]. The present Moving Average for the last 50 days of trading for this stock 108.96, while it was recorded at 103.59 for the last single week of trading, and 108.76 for the last 200 days.
Novartis AG ADR [NVS]: A deeper dive into fundamental analysis
Novartis AG ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.84 and a Current Ratio set at 1.04.
Novartis AG ADR [NVS]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novartis AG ADR go to 6.31%.
An analysis of Institutional ownership at Novartis AG ADR [NVS]
There are presently around $6.72%, or 6.72%% of NVS stock, in the hands of institutional investors. The top three institutional holders of NVS stocks are: DODGE & COX with ownership of 12.24 million shares, which is approximately 0.6019%. PRIMECAP MANAGEMENT CO/CA/, holding 12.18 million shares of the stock with an approximate value of $$1.3 billion in NVS stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $$789.58 million in NVS stock with ownership which is approximately 0.3648%.
